OKOlena Klymenko

Olena Klymenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Olena Klymenko has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hantavirus infection in Ukraine and the world: comparative analysis of the incidence dynamics of servicemen and civilians in peacetime and wartime

    by N. D. Kozak, T. Yu. Kukurudza, O. M. Vlasenko, V. V. Voronenko, O. V. Klymenko, D. O. Kozak

    Introduction. Every year, about 200 thousand cases of hantavirus infection are detected at the global level, a significant number of which have a course in the form of hemorrhagic fever with renal syndrome in Asia and Europe. The rapid course of the disease, the high mortality rate of its individual strains, which are mainly found in the Western Hemisphere, the lack of etiotropic pharmacotherapy and vaccination opportunities, as well as the characteristic features of the route of transmission of hantavirus disease (infection in the predominant most cases occurs as a result of contact with rodent body fluids), indicate that hantavirus infection remains a significant challenge to the health care system, which, nevertheless, is sporadic. Purpose. To highlight the quantitative indicators of the incidence of hantavirus infection in Ukraine among servicemen and civilians from 2014 until now in peacetime and wartime and compare them with the dynamics of incidence in specific countries and on different continents of the world. Materials and methods. In the course of forming the results of the study, the authors resorted to the bibliographic method, the method of information synthesis, comparison and generalization. The analysis of scientific literature on the subject of the work took place in the scientometric databases Scopus, PubMed, Google Scholar for the period from 2014 to the present. The value of the reliability of the approximation of the trend in the incidence of hantavirus infection among servicemen stationed in the Sumy region for the period from May to July 2025 inclusive was calculated, relative visualization was given without specifying absolute numbers, a graph of the specified trend was built, its line and equation were displayed. Results. During 2021-2026, it is worth noting the significant spatio-temporal diversity of hantavirus incidence, which is caused by the interrelated cumulative impact of the climatic features of a particular region, the transformation of ecosystems and the level of urbanization associated with the activities of the human species. In the context of the aggregate incidence of hantavirus disease among servicemen and civilians of Ukraine for the first quarter of 2026, it should be noted that a total of 63 cases of this disease were detected, which may indicate the continuation of a rapid trend and an exponential increase in the number of registered cases for the above-mentioned nosology in 2026 (as of March 2026). Conclusion. The analysis of the incidence of hantavirus infection in Ukraine from 2014 to 2026 indicates a unique epidemiological transition: from a long period of latent endemicity with sporadic case registration to a sudden epidemic outbreak in 2025-2026. In 2025, as a result of hostilities and the associated cascade of environmental factors, an increase in the incidence of this disease among the civilian population was registered in Ukraine, namely, 436 cases, of which 428 cases (which is 98.16% for the specified period) were detected in the Sumy region, which provoked an increase in the incidence among the servicemen of the Armed Forces of Ukraine stationed in the specified region, in particular, from May to July 2025 inclusive. The obtained trend of incidence dynamics for the specified period is highly reliable, since its value of the reliability of the approximation R2 is 0.8621 and this value is in the range from 0.8 to 1.0.

  • Open Access

    Pharmacological Correction of Severe Acute Pancreatitis with Pancreatogenic Diabetes Mellitus

    by Hanna Salivon, Olena Klymenko

    Introduction. Acute pancreatitis (AP) is a complex pathology in emergency abdominal surgery associated with a high risk of systemic complications. The severe course of the disease is accompanied by pancreatic necrosis, systemic inflammatory response syndrome, and multiple organ failure. The metabolic consequences of massive destructive pancreatic damage often lead to the development of secondary pancreatogenic diabetes mellitus (type 3c), which manifests as profound insular insufficiency and critical hyperglycemia, significantly limiting therapeutic options and contributing to polypharmacy. Aim. The aim of this study was to analyze the clinical and pharmacological features of managing a patient with severe acute pancreatitis, pancreatic necrosis, and secondary pancreatogenic diabetes mellitus based on a clinical case. Materials and Methods. This paper presents a retrospective analysis of the medical history of a 60-year-old patient A. with severe AP. The severity of the condition was verified according to the 2012 Atlanta classification criteria by the presence of local destructive complications and transient renal dysfunction (serum creatinine 150 μmol/L). The comprehensive diagnosis included severe acute pancreatitis, focal pancreatic necrosis, splenic vein occlusion, cholangitis, reactive hepatitis, and subcompensated pancreatogenic diabetes mellitus. Abdominal CT confirmed focal changes in the gland and the presence of heterogeneous fluid collections. Upon admission, the glycemia level reached 20.9 mmol/L, and leukocytosis was 13.4 × 10⁹/L. Results. Pharmacotherapy in the intensive care unit included infusion detoxification (Sterofundin, Reosorbilact) and antibacterial coverage of the necrosis zones (ciprofloxacin, metronidazole), which was associated with a decrease in leukocytosis to 4.0 × 10⁹/L by the seventh day. Pancreatic secretion was suppressed with omeprazole and dalargin. To improve blood rheological properties and prevent thrombosis, given a fibrinogen level of 11.5 g/L, sodium enoxaparin and pentoxifylline were utilized. During the conservative treatment phase, due to an increase in transaminases (ALT 53 U/L, AST 72 U/L), hepatoprotectors (arginine glutamate, alpha-lipoic acid) were prescribed. Special attention was paid to the correction of carbohydrate metabolism. Due to the high risk of euglycemic diabetic ketoacidosis, glycemic control in the acute period was provided by insulin therapy. The administration of the SGLT2 inhibitor dapagliflozin at a dose of 10 mg/day was performed extremely cautiously only after the resolution of acute renal dysfunction (creatinine reduction to 102 μmol/L on the third day), stabilization of overall hemodynamics, restoration of hydration balance, and the patient's transition to oral nutrition. Conclusions. The described clinical case demonstrates the successful implementation of an individualized pharmacological strategy; however, proving the isolated efficacy of specific agents, such as dalargin or hepatoprotectors, is limited by the scope of a single observation. The use of SGLT2 inhibitors in the acute period of pancreatic necrosis cannot be considered a routine recommendation and requires dynamic monitoring of electrolytes, renal function, and acid-base status.

  • Open Access

    Ozempic: the gold standard for weight normalisation or a “lifeboat”

    by Hanna Salivon, Olena Klymenko

    Obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome remain prevalent global health challenges requiring comprehensive management strategies. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has emerged as a significant pharmacological intervention. The study aims to analyze current scientific data to critically assess the clinical efficacy and safety of semaglutide (Ozempic) in treating T2DM and obesity, determining its position in modern therapeutic protocols. A descriptive review of the literature was conducted, analyzing key phase III clinical trials, including the SUSTAIN, PIONEER, STEP, and SELECT programmes. The review focuses on pharmacokinetic properties, glycaemic control, weight loss outcomes, and cardiovascular safety profiles of both subcutaneous and oral semaglutide formulations. Clinical trials demonstrate that semaglutide significantly reduces glycated haemoglobin (HbA1c) by -1.0% to -1.8% and induces substantial weight loss(averaging ~15%), surpassing earlier GLP-1RAs. The drug exhibits pleiotropic effects, including improved endothelial function and reduced inflammation, contributing to cardiovascular protection, with a relative reduction of major adverse cardiovascular events (MACE) by ~20%. However, rapid weight regains upon discontinuation and potential adverse effects such as gastrointestinal disturbances remain significant concerns. Semaglutide represents a highly effective pharmacological option for managing metabolic disorders, offering benefits beyond glycaemic control. While it sets a high standard for efficacy, issues regarding cost, accessibility, and the necessity for long-term adherence categorize it as a specialized resource requiring strategic implementation rather than a universally accessible cure.

  • Signaling pathways in the mechanisms of drug action

    by Nadiya Gorchakova, Tatyana Harnyk, Igor Belenichev, Valeriia Hnatiuk, Olena Shumeіko, Olena Klymenko, Ella Gorova, Kateryna Romanova

  • Open Access

    Pharmacological management of obstetric hemorrhage

    by Rostyslav Yarotsky, Olena Klymenko

    Postpartum hemorrhage is an emergency in obstetrics, which is one of the five most common causes of maternal mortality. Knowledge of all algorithms and protocols for childbirth, providing assistance in the event of an emergency is the key to reducing maternal mortality and delayed negative health consequences for both the mother and the newborn. The aim of the work was to study the protocols and management of postpartum obstetric hemorrhage. Upon hospitalization, the pregnant woman undergoes laboratory and instrumental examination, the doctor assesses the risk group for postpartum obstetric hemorrhage. First pregnancy, 36 weeks. Twin, bichorionic, biamniotic. History of primary infertility. Pregnancy occurred with the use of additional reproductive technologies. According to the results of the examination, moderate preeclampsia, secondary thrombocytopenia were noted. A cesarean section was performed and one of the main points of highly professional care for postpartum hemorrhage is the administration of drugs: a hormonal preparation of the posterior pituitary gland - oxytocin, an agonist of oxytocin receptors - carbetocin, a fibrinolysis inhibitor - tranexamic acid and prostaglandins - misoprostol; to prevent and eliminate hypochromic anemia - iron preparations in accordance with the approved protocol.

  • Phytodrugs Combined with Pharmacotherapy Agents for the Treatment of Neurodegenerative Diseases (research literature review)

    by Nadiya Gorchakova, Tatyana Harnyk, Ulyana Lushchyk, Olena Shumeyko, Olena Klymenko, Natalia Savchenko, Anna Doroshenko, Olga Ryzhenko

  • Stress protection properties of phytodrugs

    by Nadiya Gorchakova, Igor Belenichev, Tatyana Harnyk, Ganna Zaychenko, Olena Klymenko, Ella Gorova, Olena Shumeyko, Iryna Maslova

  • Open Access

    Data from Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer

    by Peter Weber, Axel Künstner, Julia Hess, Kristian Unger, Sebastian Marschner, Christian Idel, Julika Ribbat-Idel, Philipp Baumeister, Olivier Gires, Christoph Walz, et al.

    Purpose:The genetic relatedness between primary and recurrent head and neck squamous cell carcinomas (HNSCC) reflects the extent of heterogeneity and therapy-driven selection of tumor subpopulations. Yet, current treatment of recurrent HNSCC ignores the molecular characteristics of therapy-resistant tumor populations.Experimental Design:From 150 tumors, 74 primary HNSCCs were RNA sequenced and 38 matched primary/recurrent tumor pairs were both whole-exome and RNA sequenced. Transcriptome analysis determined the predominant classical (CL), basal (BA), and inflamed-mesenchymal (IMS) transcriptional subtypes according to an established classification. Genomic alterations and clonal compositions of tumors were evaluated from whole-exome data.Results:Although CL and IMS subtypes were more common in primary HNSCC with low recurrence rates, the BA subtype was more prevalent and stable in recurrent tumors. The BA subtype was associated with a transcriptional signature of partial epithelial-to-mesenchymal transition (p-EMT) and early recurrence. In 44% of matched cases, the dominant subtype changed from primary to recurrent tumors, preferably from IMS to BA or CL. Expression analysis of prognostic gene sets identified upregulation of hypoxia, p-emt, and radiotherapy resistance signatures and downregulation of tumor inflammation in recurrences compared with index tumors. A relevant subset of primary/recurrent tumor pairs presented no evidence for a common clonal origin.Conclusions:Our study showed a high degree of genetic and transcriptional heterogeneity between primary/recurrent tumors, suggesting therapy-related selection of a transcriptional subtype with characteristics unfavorable for therapy. We conclude that therapy decisions should be based on genetic and transcriptional characteristics of recurrences rather than primary tumors to enable optimally tailored treatment strategies.

  • Open Access

    Supplementary Figure from Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer

    by Peter Weber, Axel Künstner, Julia Hess, Kristian Unger, Sebastian Marschner, Christian Idel, Julika Ribbat-Idel, Philipp Baumeister, Olivier Gires, Christoph Walz, et al.

    Supplementary Figure from Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer

  • Membranotropic action of phytodrugs

    by Nadiya Gorchakova, Igor Belenichev, Tatyana Harnyk, Olena Shumeyko, Olena Klymenko